Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 5, 2001, Pages 1438-1443

  Mittler, J ^a   Essunger, P ^a   Yuen, G J ^a   Clendeninn, N ^a   Markowitz, M ^a   Perelson, A S ^a  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NELFINAVIR; VIRUS RNA;

ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; NELFINAVIR; RETROSPECTIVE STUDIES; RNA, VIRAL;

EID: 0035028250     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.5.1438-1443.2001     Document Type: Article

References (41)

1. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir
2. Resistance to human immunodeficiency virus type 1 protease inhibitors
3. Virus dynamics and drug therapy
4. Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma
5. Regional survival differences across Europe in HIV-positive people: The EuroSIDA study
6. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine
7. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease
8. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome
9. Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics
10. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study
11. HIV infection: How effective is combination treatment?
12. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior anti-retroviral therapy
13. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
14. Viral dynamics in vivo: Limitations on estimates of intracellular delay and virus decay
15. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
16. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
17. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir
18. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
19. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
20. Impact of drug resistance mutations on virologic response to salvage therapy
21. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection
22. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection
23. Population dynamics of HIV within an individual after treatment with zidovudine
24. Changing patterns of mortality across Europe in patients infected with HIV-1
25. Individual prognoses of long-term responses to antiretroviral treatment based on virological, immunological and pharmacological parameters measured during the first week under therapy
26. Rate of decline of HIV-1 following antiretroviral therapy is related to viral load at baseline and drug regimen
27. Anti-viral drug treatment: Dynamics of resistance in free virus and infected cell populations
28. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
29. Decay characteristics of HIV-1-infected compartments during combination therapy
30. Dynamics of HIV infection of CD4+ T cells
31. Mathematical analysis of HIV-1 dynamics in vivo
32. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time
33. Inhibitors of human immunodeficiency virus integrase
34. Antigen-specific T-lymphocyte proliferative responses during highly active antiretroviral therapy (HAART) of HIV-1 infection
35. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
36. Vigorous HIV-1-specific CD4(+) T cell responses associated with control of viremia
37. Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease
38. Immune function and phenotype before and after highly active anti-retroviral therapy
39. Anti-human immunodeficiency virus drug combination strategies
40. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads
41. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy